Prognosis and Clinicopathology of CXCR4 in Colorectal Cancer Patients: a Meta-analysis

  • Li, Lu-Ning (Department of Gastroenterology, Linyi People's Hospital) ;
  • Jiang, Kai-Tong (Department of Gastroenterology, Linyi People's Hospital) ;
  • Tan, Peng (Internal medicine teaching and research section of Shandong Medical College) ;
  • Wang, Ai-Hua (Department of Gastroenterology, Linyi People's Hospital) ;
  • Kong, Qing-Yin (Department of Gastroenterology, Linyi People's Hospital) ;
  • Wang, Cui-Yue (Department of Gastroenterology, Linyi People's Hospital) ;
  • Lu, Hua-Rong (Department of Gastroenterology, Linyi People's Hospital) ;
  • Wang, Jing (Department of Hepatology, Provincial Hospital Affiliated to Shandong University)
  • Published : 2015.05.18


The chemokine receptor 4 (CXCR4) has been widely used in diagnosis and prognosis of colorectal cancer (CRC). However, there is no current consensus on the impact of CXCR4 on CRC patients. The purpose of this study was to evaluate the prognostic and clinicopathological importance of CXCR4 in CRC patients. Databases, such as PubMed, Cochrane library, CBM and EMBASE updated to 2014 were searched to include eligible articles. We analysed correlations between CXCR4 expression and clinicopathological features and overall survival (OS). A total of 1, 055 CRC patients from twelve studies were included in the study. The pooled odds ratios (ORs) which indicated CXCR4 expression was likely to be associated with TNM stage (OR=0.43, CI=0.34-0.55, P<0.00001), lymph node status (OR=2.23, CI=1.23-4.05, P=0.008) and vascular invasion (OR=2.21, CI=1.11-4.39, P=0.02). Poor overall survival of CRC cancer was found to be significantly related to CXCR4 overexpression (hazard ratio (HR) 1.36 CI=1.17-1.59, P<0.0001), whereas combined ORs revealed that CXCR4 expression had no correlation with gender or differentiation. Based on the published studies, CXCR4 overexpression in patients w ith CRC indicates poor survival outcome and clinicopathological factors.


  1. Alessandro Ottaiano, Renato Franco, Annarita Aiello Talamanca, et al (2006). Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage ii-iii colorectal cancer patients. Clin Cancer Res, 12, 2795-803.
  2. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer, 4, 540-50.
  3. Crescenzo D'Alterio, Antonio Avallone, Fabiana Tatangelo, et al (2013). A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. Int J Cancer, 135, 379-90.
  4. Frank M, Gerrit Jan, Cornelis J, et al (2009). Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenvironment, 2, 1-7.
  5. Fukunaga S, Maeda K, Noda E, et al (2006). Association between expression of vascular endothelial growth factor c, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology, 71, 204-11.
  6. Hao L, Zhang C, Qiu Y, et al (2007). Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer. Cancer Letters, 253, 34-42.
  7. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  8. Joseph Kim, Hiroya Takeuchi, Stella T. Lam, et al (2005). Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival. J Clin Oncol, 23, 2744-53.
  9. Kang Y, Siegel PM, Shu W, et al (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer cell, 3, 537-49.
  10. Kim J, Takeuchi H, Lam ST, et al (2005). Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol, 23, 44-53.
  11. Kucia M, Jankowski K, Reca R, et al (2004). CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol, 35, 233-45.
  12. Li XF, Guo XG, Yang YY et al., (2015). Effect of CXCR4 and CD133 co-expression on the prognosis of patients with stage II-III colon cancer. Asian Pac J Cancer, 16, 1074-76
  13. Luker KE and Luker GD (2006). Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett, 238, 30-41.
  14. Matsusue R, Kubo H, Hisamori S, et al (2009). Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol, 16, 2645-53.
  15. Ottaiano A, Franco R, Aiello Talamanca A, et al (2006). Overexpression of both CXC chemokine receptor 4 and vascular endothelial factor predicts early distant relapse in Stage II-III colorectal cancer patients. Clin Cancer Res, 12, 2795-803.
  16. Romain B, Hachet-Haas M, Rohr S et al (2014). Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer, 13, 58
  17. Saur D, Seidler B, Schneider G (2005). CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterol, 129, 1237-50.
  18. Schimanski CC, Schwald S, Simiantonaki N, et al (2005). Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res, 11, 1743-50.
  19. Shinichiro Yamada, Mitsuo Shimada, Tohru Utsunomiya, et al (2014). CXC receptor 4 and stromal cell-derived factor 1 in primary tumors and liver metastases of colorectal cancer.J Surg Res, 187, 107-12.
  20. Shang-Chiung Wang, Jen-Kou Lin, Huann-Sheng Wang, et al (2010). Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis, 25, 1185-91.
  21. Stetler Stevenson WG, Kleiner DE Jr (2001). Molecular biology of cancer: invasionand metastasis. In: devita vt jr, hellman s, rosenberg sa, editors. cancer: principles and practice of oncology. philadelphia, PA: Lippincott Williams, 2001, 123-36.
  22. Tinghua Hu, Yu Yao, Shuo Yu, et al (2013). Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer. J Biom Res, 27, 283-90.
  23. Ying Gao, Chunyu Li, Min Nie, et al (2014). CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer. Tumor Biol, 35, 4171-5.
  24. Yopp AC, Shia J, Butte JM, et al (2012). CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol, 19, 339-46.
  25. Yoshitake N, Fukui H, Yamagishi H, et al (2008). Expression of SDF-1aand nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer, 98, 1682-89.
  26. Yugang Wu, Min Jin, Huanbai Xu, et al (2010). Clinicopathologic Significance of HIF-1${\alpha}$, CXCR4, and VEGF Expression in Colon Cancer. Clin Developml Immunol.

Cited by

  1. The Role of p-STAT3 as a Prognostic and Clinicopathological Marker in Colorectal Cancer: A Systematic Review and Meta-Analysis vol.11, pp.8, 2016,
  2. Phosphorylated CXCR4 expression has a positive prognostic impact in colorectal cancer vol.40, pp.6, 2017,